Dr. King founded Surgicure Technologies at age 20 while studying neuroscience, driven by deeply personal medical experiences that instilled a conviction that trauma patients deserve better tools, better outcomes and leaders who understand the human cost of system failure. She has contributed to a National Institutes of Health-funded Alzheimer’s vaccine development program and a Gates Foundation-funded HIV biomarker study. Meanwhile, her exposure to respiratory failure during the Covid-19 years directly shaped Surgicure’s clinical focus. Discovering a shelved Army clinician-developed airway securement technology that addressed a critical patient safety gap, she independently validated unmet need by interviewing frontline clinicians across civilian and military care settings, cold-called the U.S. Army technology transfer office to license the patent, and bootstrapped Surgicure from the ground up as a solo founder for over five years, leading product development, clinical validation, regulatory navigation and early commercialization. This work evolved into Surgicure’s flagship airway securement platform, developed through deep collaboration with clinicians, nurses and first responders, which within months of commercial launch secured an exclusive U.S. distribution partnership and began deployment across hospital systems and frontline war zone care settings. Beyond Surgicure, she is an active mentor within Boston’s innovation ecosystem, and was named a BostInno “40 Under 40” honoree in 2025, received a citation of recognition from the Executive Office of Economic Development on behalf of Governor Maura Healey in 2024, and is a National Science Foundation graduate research fellowship recipient.
